Archive for the ‘Trubion Pharmaceuticals’ Category

CEO took roundabout path to Emergent

By Marjorie Censer
Monday, January 3, 2011
Fuad El-Hibri has lived in all sorts of exotic locales, working for Citicorp in Saudi Arabia, consulting for Booz Allen Hamilton in Indonesia and establishing mobile telecommunications businesses in Russia, Venezuela and El Salvador.
But getting started in his current position as chief executive of Rockville-based pharmaceutical company Emergent BioSolutions took [...]

January 7, 2011  Tags: , , , , ,   Posted in: Biosolutions, Business, CEO, Department of Health and Human Services, El-Hibri, Emergent BioSolutions, Research and development, Trubion Pharmaceuticals, Yale University, fuad, fuad el-hibri  No Comments

Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals

ROCKVILLE, Md., Oct 28, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the acquisition of Trubion Pharmaceuticals, Inc., following a majority vote to approve the merger by Trubion stockholders at a special meeting conducted at Trubion’s Seattle headquarters on October 28, 2010. The acquisition [...]

November 3, 2010  Tags: , , , ,   Posted in: Business, Emergent BioSolutions, Seattle, Trubion Pharmaceuticals, fuad el-hibri  No Comments

Emergent BioSolutions to Acquire Trubion Pharmaceuticals

Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income

ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]

August 19, 2010  Tags: , , , , , , ,   Posted in: Africa, Anthrax vaccines, Biosolutions, Emergent BioSolutions, Health Care, Management, Research and development, Share, Trubion Pharmaceuticals, fuad el-hibri  No Comments